Man Group’s Kindred Biosciences, Inc. KIN Stock Holding History

Man Group’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-67,540	Closed	-$942K	–	2199
2018 Q3	$942K	Buy	+67,540	New	+$914K	﹤0.01%	1688

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's KIN Position: Q4 2018 in Review

Man Group sold out of Kindred Biosciences, Inc. (KIN) in Q4 2018, closing a stake of 67,540 shares — an estimated $942K sold.

Man Group first reported a position in KIN in Q3 2018 and held it in 1 quarter. The position peaked at $942K in Q3 2018. 72 funds tracked by Wall St. Rank hold KIN as of Q4 2018.

Man Group reported no remaining Kindred Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
Man Group sold 67,540 Kindred Biosciences, Inc. shares in Q4 2018, an estimated $942K.
Man Group first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 1 quarter.
Man Group's Kindred Biosciences, Inc. position peaked at $942K in Q3 2018.
72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2018.

Based on Man Group's 13F filing for Q4 2018, filed 14 Feb 2019.